VNRX · Volitionrx Ltd

The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old' options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old' options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

In connection with his employment as Chief Executive Officer of Volition Veterinary Diagnostics Development, LLC, Dr. Butera received restricted stock units subject to a 3-year vesting schedule, vesting as to 50,000 units on each of 05/01/22, 05/01/23 and 05/01/24, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

Mr. Brudnick received restricted stock units subject to a 2-year vesting schedule, vesting as to 7,500 units on each of 03/25/22 and 03/25/23, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

Ms. Nguyen received restricted stock units subject to a 2-year vesting schedule, vesting as to 7,500 units on each of 03/25/22 and 03/25/23, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

The reported transaction involved a cancellation of unvested restricted stock units upon Dr. Butera's resignation as a director of the issuer.

On February 1, 2021, the Reporting Person was granted a warrant to purchase up to 185,000 shares of Common Stock of the issuer at an exercise price of $4.90 per share. The warrant will vest in full twelve months from the date of grant (subject to continuous employment through such date).

The option to purchase an aggregate of 125,000 shares of Common Stock of VolitionRx Limited (the "Issuer"), was granted to Dr. Micallef on April 15, 2016 under the Issuer's 2015 Stock Incentive Plan and transferred to Borlaug Limited ("Borlaug"), a consulting firm, on April 20, 2016. Dr. Micallef is a controlling director of Borlaug and has voting and dispositive control over the Common Stock issuable to Borlaug upon the exercise of the option. The option was then transferred by Borlaug to Dr. Micallef on December 22, 2020.

The option to purchase an aggregate of 60,000 shares of Common Stock of VolitionRx Limited (the "Issuer"), was granted to Mr. Vanston on January 23, 2018, under the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"). The option was transferred as a gift by Mr. Vanston to his daughter on December 22, 2020. Mr. Vanston disclaims beneficial ownership of the shares held by his daughter.

The option to purchase an aggregate of 60,000 shares of Common Stock of VolitionRx Limited (the "Issuer"), was granted to Mr. Vanston on January 23, 2018, under the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"). The option was transferred as a gift by Mr. Vanston to his daughter on December 22, 2020. Mr. Vanston disclaims beneficial ownership of the shares held by his daughter.

The option to purchase an aggregate of 50,000 shares of Common Stock of the Issuer was granted to Mr. Vanston on February 11, 2019 under the Issuer's 2015 Plan. The option was transferred as a gift by Mr. Vanston to his daughter on December 22, 2020. Mr. Vanston disclaims beneficial ownership of the shares held by his daughter.

The option to purchase an aggregate of 125,000 shares of Common Stock of VolitionRx Limited (the "Issuer"), was granted to Dr. Micallef on April 15, 2016 under the Issuer's 2015 Stock Incentive Plan and transferred to Borlaug Limited ("Borlaug"), a consulting firm, on April 20, 2016. Dr. Micallef is a controlling director of Borlaug and has voting and dispositive control over the Common Stock issuable to Borlaug upon the exercise of the option. The option was then transferred by Borlaug to Dr. Micallef on December 22, 2020.

The option to purchase an aggregate of 50,000 shares of Common Stock of the Issuer was granted to Mr. Vanston on February 11, 2019 under the Issuer's 2015 Plan. The option was transferred as a gift by Mr. Vanston to his daughter on December 22, 2020. Mr. Vanston disclaims beneficial ownership of the shares held by his daughter.

Dr. Butera received restricted stock units subject to a 2-year vesting schedule, vesting as to 7,500 units on each of 12/01/21 and 12/01/22, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

On September 18, 2020, the Reporting Person exercised a warrant to purchase 25,000 shares of Common Stock of the issuer for $2.47 per share. The warrant was set to expire pursuant to its terms on September 18, 2020.

The shares of Common Stock were sold by the reporting person in a private transaction to Lagoda Investment Management, L.P., an existing stockholder of the Issuer.

Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation as payment of the exercise price in a cashless exercise by the Reporting Person. No shares were sold by the Reporting Person or VolitionRx in such cashless exercise transaction.

Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation as payment of the exercise price in a cashless exercise by the Reporting Person. No shares were sold by the Reporting Person or VolitionRx in such cashless exercise transaction.